Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine
Pietro Lampertico, Mauro Viganò, Elena Manenti, Massimo Iavarone, Giovanna Lunghi, Massimo Colombo – 29 November 2005 – Progression of hepatitis B in patients with lamivudine‐resistant strains is slowed down by adefovir dipivoxil (ADV). Whether the time point of ADV administration (genotypic vs. phenotypic resistance) influences the outcome of therapy is unknown. We compared the outcome of ADV therapy in hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B patients with genotypic and phenotypic resistance to lamivudine.